Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Steven Klosk
AddedFeb 15, 2024
UpdatedMay 31, 2026
Steven Klosk

Steven Klosk

Board Member, Lisata Therapeutics

CrunchbaseLinkedInThe Org

Steven Klosk's Career

Lisata Therapeutics
Lisata Therapeutics

Basking Ridge, NJ, US

Board Member· Board
NJ Bio
NJ Bio

Princeton, NJ, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Steven Klosk's Career

Lisata Therapeutics
Lisata Therapeutics
Public$165.6M5001980Basking Ridge, NJ, US
Board Member· Board

Leadership at Lisata Therapeutics

Erkki RuoslahtiErkki RuoslahtiCo-Founder
Anastasia MannAnastasia MannBoard Member
Cynthia SchwalmCynthia SchwalmBoard Member
David J. MazzoDavid J. MazzoCEO
Catherine VaczyCatherine VaczyCo-Founder
Mohammad AzabMohammad AzabBoard Member

Similar to Lisata Therapeutics

Lusaris TherapeuticsLusaris TherapeuticsBoston, MA, USTherapeuticsest. 2021Lusaris TherapeuticsBoston, MA, US · est. 2021

Lusaris: A biotech firm pioneering advanced therapeutics for severe neuropsychiatric disorders.

Series A · $60M6
Thetis PharmaceuticalsThetis PharmaceuticalsRidgefield, CT, USDrug Developmentest. 2011Thetis PharmaceuticalsRidgefield, CT, US · est. 2011

Thetis Pharmaceuticals: Specializing in cardio-metabolic, cancer, and autoimmune disease treatments.

Series A · $22.9M30
Lyst TherapeuticsLyst TherapeuticsColumbus, OH, USHealth Researchest. 2015Lyst TherapeuticsColumbus, OH, US · est. 2015

Lyst Therapeutics: Pioneering health research to inhibit vascular graft stenosis at Nationwide Children's Institute.

Seed · $400k6
Lysosomal TherapeuticsLysosomal TherapeuticsCambridge, MA, USDrug Developmentest. 2011Lysosomal TherapeuticsCambridge, MA, US · est. 2011

US-based Lysosomal Therapeutics Inc innovates in neurodegeneration research, developing treatments for severe neurological diseases.

Series A · $24.8M5
NJ Bio
NJ Bio
Series A$5.6M1112019Princeton, NJ, US
Board Member· Board

Leadership at NJ Bio

Chetan JainChetan JainBoard Member
Nareshkumar JainNareshkumar JainBoard Member
Ronald GoldRonald GoldBoard Member

Steven Klosk's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Steven Klosk

Gregg MichaelsonGregg MichaelsonBoard Member · Signet AccelChristopher KerseyChristopher KerseyBoard Member · MetabolonRajesh NambiarRajesh NambiarBoard Member · TrizettoGreg SchottGreg SchottBoard Member · ConfluentJeffrey LeventhalJeffrey LeventhalFounder · S12FKen CarterKen CarterBoard Member · BioHealth Innovation